Shots:

• The US FDA has granted BTD for IMGN632 to treat relapsed or refractory BPDCN
• The BTD was based on findings from the BPDCN cohort of the first-in-human study of IMGN632- for which initial data were presented in ASH 2019. Updated data from the IMGN632 monothx. BPDCN dose expansion cohort will be presented at ASH in Dec’2021
• MGN632 is a CD123-targeting ADC and is currently evaluated in multiple cohorts- including monothx. for patients with BPDCN and MRD+ AML following frontline induction therapy and in combinations with Vidaza (azacitidine) and Venclexta (venetoclax) for patients with relapsed/refractory AML

 ­ Ref: PRNewswire | Image: PRNewswire